Connect with us

Stock Market Breaking News

Premier Health (OTC:P​HGRF) (CSE:P​HGI) Partnering with Bio Conscious Technologies to bring AI Powered Remote Patient Monitoring to its App

Daniel Chase

Published

on

stock_price_cancer

VANCOUVER, British Columbia, March 13, 2019 (GLOBE NEWSWIRE) — Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce it is working with Bio Conscious Technologies (BCT) to bring their Artificial Intelligence (AI) technology to Premier Health’s user base.

Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT’s proprietary AI technology.

Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond

BCT has been developing an ensemble of AI algorithms since 2015 that allow patients with diabetes to better manage their health proactively by accurately predicting their future glucose levels using machine learning techniques. The World Health Organization estimates that 425 million people are living with diabetes. Mismanagement of diabetes can be very harmful. BCT’s algorithm, DiaBits, learns an individual’s physiology and predicts, with machine learning technology, where their blood sugar will trend over time based on their past trend, behaviour, and activity. BCT successfully piloted its technology at BC Children’s Hospital, resulting in a proven accuracy of 95%. They also presented at the 78th scientific session of the American Diabetes Association. The companies will work on integrating DiaBits into Premier Health’s patient-centric healthcare app.

“Since the beginning, remote patient monitoring has been an integral component of our telemedicine app,” said Dr. Essam Hamza, CEO of Premier Health. “DiaBits will enable our diabetic patients to dramatically increase glucose control and improve their quality of life. We are eager to work with the team at BCT to bring this innovative solution to our comprehensive telemedicine app.”

“We are excited to be selected by Premier Health to partner for our remote health monitoring technology,” said Amir Hayeri, CEO of BCT. “Incorporating the DiaBits technology platform into Premier Health’s app will reduce the guesswork associated with managing diabetes and result in diabetic users having fewer sugar highs, and fewer sugar lows, all while delaying the onset of complications. We are also in the works for developing similar technologies that predict high blood-pressure and premature contractions for pregnant women at risk of pre-eclampsia.”

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”
Chief Executive Officer

About Premier Health

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are focused on innovative health care approaches that combine human skill-based expertise with emerging technologies. Premier Health, in conjunction with its subsidiary Cloud Practice, a cloud-based SAAS Electronic Medical Records software company, is developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have a combined ecosystem of 290 clinics, over 3000 licensed practitioners and almost 3 million registered patients. The Premier Health team has deep clinical, operational and financial expertise and a passion for improving healthcare for all patients.

About Bio Conscious Technologies

Bio Conscious Technologies is a health analytics company. Their mission is to enable patients and care providers to better understand and treat diseases using intelligent analytics. Their app, DiaBits, allows diabetic users to manage their health without stress. Their multivariate algorithm learns an individual user’s physiology and predicts where their blood sugar will trend over time based on their behavior and activity. With DiaBits, users have more glucose control, less Hypo and Hyperglycemia episodes, and better long-term health outcomes.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FOR ADDITIONAL INFORMATION CONTACT:

Premier Health Group Inc.
www.mypremierhealth.com 
Email: investors@mypremierhealth.com 

DISCLAIMER: Pursuant to an agreement between MIDAM VENTURES, LLC  and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Please click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

PharmaCyte Biotech (PMCB) Appoints Cellular Expert to Medical and Scientific Advisory Board

Joe Samuel

Published

on

biotech penny stocks to buy

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Most importantly, Mr. Judd has worked for many years with the cells that PharmaCyte uses in its treatment of cancer and has a wealth of knowledge regarding their growth properties.


[Free Report] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company


PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We feel the appointment of Mr. Judd to our Medical and Scientific Advisory Board comes at a crucial time as we work with our colleagues at Austrianova to conduct the final manufacturing runs to produce successfully the encapsulated cells that are needed for our clinical trial in locally advanced, non-metastatic, pancreatic cancer.”

Mr. Waggoner continued, “Mr. Judd was so intrigued by the possibility that our platform technology may change the way many solid tumors are treated, with little to no chemotherapy side effects, that he volunteered to work with us months ago. He has made significant contributions to our efforts in working with Austrianova to ensure that the cells from our Master Cell Bank grow as they should, both pre and post-encapsulation. During a critical time in realigning certain aspects of the manufacturing process, Mr. Judd accompanied us as an advisor to Austrianova’s cGMP manufacturing facility in Bangkok, Thailand, where the encapsulation of our cells is taking place.

“In a recent video interview, which can be viewed at www.PharmaCyte.com/Media, I spoke to why we selected Mr. Judd to join our team and the contributions he has already made to our Cancer Program. We believe that Mr. Judd’s talents and expertise will be invaluable in the development of cellular therapies for cancer as well as our efforts in the development of cellular therapies for diabetes.”

Mr. Judd is a graduate of the Biotechnology program at Rochester Institute of Technology, the first Biotechnology program in the United States. He has over 30 years of experience in cell culture and biochemistry in research and in a cGMP environment. Also, he has extensive experience in research and development of cell culture medium, both in the upstream and downstream processes.

Mr. Judd is currently employed by the Grand Island Biotechnology Company (Gibco) and is involved in research, process development and cGMP production of biotechnology and cell therapy processes.

Mr. Judd has been employed by Gibco (now owned by ThermoFischer Scientific) for 29 years and is a co-inventor on 5 patents involving cell culture materials.

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Continue Reading

Featured

Stock Price Monday Morning Update – July 15, 2019

A. Lawrence

Published

on

stock price today

List Of Biotech Stocks To Watch This Quarter

Biotech has been one of the hottest sectors for the past few years. Much of that is due to the fact that there are many biotech stocks doing highly innovative work.

Click To Read More


3 Tech Stocks To Watch For July

For the past few decades, tech stocks have almost always been the most popular stocks in the market. Considering the sort of returns some of the tech giants have generated over decades, it doesn’t come as a surprise.

Click For More


Gold Prices Have Investors Scrambling & Analysts Clamoring For Junior Gold Stocks

Gold has long been a safe haven stock. But as the market turned toward tech, precious metal stocks took a back seat…until now. Could the timing of gold’s next bull run be perfect right now?

Continue Reading

Continue Reading

Featured

A Very Active Quarter For IPOs Raising About $25 Billion Capital

Jon Phillip

Published

on

IPO Stocks

It seems like it has been a great time for new IPO stocks this quarter. From a very slow Q1 to Q2 becoming the most active quarter (based on the number of deals) over four years, the first half of 2019 has been quite a surprise to many investors.

While there had been forecasts suggesting more than 200 new IPOs to happen in 2019, Q2 saw 62 companies going for IPO. These new stocks raised total capital $25 billion. This is the highest capital raised within the past 5 years. The rate of return on an average was 30%. This signifies a great start to going public. There were a few major industries that dominated IPOs in Q2 like technology and biotech. While IPOs of energy-based companies and the financial sector fell way below average.

New IPO Stocks Raise Eyebrows

The IPO investors are in for quite some benefits with initial price being reasonable even though below than the competitors publically traded ones, claims Kathleen Smith an IPO tracker at Renaissance Capital. The best performer in the IPO market includes Beyond Meat (BYND)- a plant-based food maker which is up by 542%. Pinterest (PINS) (+38%) closely followed second. Zoom Video (ZM) (+140%), Slack (WORK) (+39%), Chewy (CHWY) (+50%), and CrowdStrike (CRWD) (+89%) also gave a notable performance.

However, the most anticipated IPO of $8.1 billion the Uber IPO (UBER) disappointed the market by a fall in value of 8% on the first day. The Lyft IPO, a competitor of Uber, shared the same fate and is down by 12%. These are just exceptions in the plush IPO market in Q2. Presently, there are 60 companies hoping to raise about $11 billion, the majority of which has been already filed. Among these 60 include WeWork, Peloton, Postmates, Casper, Poshmark, and Airbnb.

If this bullish IPO market trend continues, then, it could mean a record braking year. The record stands at $96.9 billion raised from 2000. This is probably a prime time for private companies to venture into the public market domain. 

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com